NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine

Antiviral Research

Volumn 76, Issue 2, 2007, Pages 99-103

  Paolucci, Stefania ^a   Baldanti, Fausto ^a,b   Campanini, Giulia ^a   Cancio, Reynel ^c   Belfiore, Amalia ^c   Maga, Giovanni ^c   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Laboratori Sperimentali di Ricerca   (Italy)

^c CNR   (Italy)

Author keywords

Drug resistance; HIV 1; NNRTI; NRTI; RT mutations

Indexed keywords

NEVIRAPINE; RECOMBINANT ENZYME; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; CATALYSIS; CODON; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS RECOMBINANT; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34548771682     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.06.002     Document Type: Article

References (17)

1. Baldanti F., Paolucci S., Maga G., Labò N., Hubscher U., Skoblov A.Y., Victorova L., Spadari S., Minoli L., and Gerna G. Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. AIDS 17 (2003) 1568-1570
2. Blanca G., Baldanti F., Paolucci S., Yu Skoblov A., Victorova L., Hubscher U., Gerna G., Spadari S., and Maga G. Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity. J. Biol. Chem. 278 (2003) 15469-15472
3. Boyer P.L., Gao H.Q., and Hughes S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42 (1998) 447-452
4. Fan N., Rank K.B., Slade D.E., Poppe S.M., Evans D.B., Kopta L.A., Olmsted R.A., Thomas R.C., Tarpley W.G., and Sharma S.K. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry 35 (1996) 9737-9745
5. Huang W., Gamarnik A., Limoli K., Petropoulos C.J., and Whitcomb J.M. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 77 (2003) 1512-1523
6. Hu Z., Giguel F., Hatano H., Reid P., Lu J., and Kuritzkes D.R. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J. Virol. 80 (2006) 7020-7027
7. Kleim J.P., Rosner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., Arnold E., and Riess G. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74->Val or Ile and Val-75->Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 34-38
8. Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Def. Syndr. 26 Suppl. 1 (2001) S10-S24
9. Maga G., Amacker M., Ruel N., Hubscher U., and Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 274 (1997) 738-747
10. Matamoros T., Franco S., Vazquez-Alvarez B.M., Mas A., Martinez M.A., and Menendez-Arias L. Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers. J. Biol. Chem. 279 (2004) 24569-24577
11. Miller V., and Larder B.A. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir. Ther. 6 Suppl. 3 (2001) 25-44
12. Paolucci S., Baldanti F., Maga G., Cancio R., Zazzi M., Zavattoni M., Chiesa A., Spadari S., and Gerna G. Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication. Antimicrob. Agents Chemother. 48 (2004) 4611-4617
13. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Cheng-Kon S., Myers M., and Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68 (1994) 1660-1666
14. Selmi B., Deval J., Alvarez K., Boretto J., Sarfati S., Guerreiro C., and Canard B. The Y181C substitution in 3′-azido-3′deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the in 3′-azido-3′deoxythymidine 5′-monophosphate-terminated primer. J. Biol. Chem. 42 (2003) 40464-40472
15. Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., Rice P.A., and Steitz T.A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3911-3915
16. Van Laethem K., Witvrouw M., Pannecouque C., Van Remoortel B., Schmit J.C., Esnouf R., Kleim J.P., Balzarini J., Desmyter J., De Clercq E., and Vandamme A.M. Mutations in the non-nucleoside binding-pocket interfere with the multinucleoside resistance phenotype. AIDS 15 (2001) 553-561
17. Lys,3 that correlate with reductions in replication efficiency. Virology 348 (2006) 462-474